PD 130908 is an analogue of RSU 1069 and is an effective hypoxic cytotoxin, but less potent than the hypoxic cell radiosensitizer RSU 1069. Toxicity toward hypoxic tumor cells in vivo is demonstrated by clamping tumors (for 60 min) following administration of PD 130908. Systemic toxicity is substantially reduced following orally bioavailable drug administration. Further, doses achievable following fractionated drug treatments are sufficiently high to produce significant levels of radiosensitization. References: Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908. Int J Radiat Oncol Biol Phys. 1992;22(3):545-8. PubMed PMID: 1735694. 2: Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents. Int J Radiat Oncol Biol Phys. 1992;22(3):549-51. PubMed PMID: 1531213.

纯度：≥98%

CAS：131505-02-7